Table 1.
Baseline data.
| Parameter | Placebo | Melatonin |
|---|---|---|
| ITT Population (N = 314) | N = 151 | N = 163 |
| Age, years (median, [IQR]) | 39 [31, 49] | 41 [32, 49.5] |
| Female sex, n (%) | 123 (81.5%) | 132 (81%) |
| Blood pressure (median, [IQR]) | ||
| Systolic | 118.00 [110.00, 128.00] | 116.00 [105.00, 125.00] |
| Diastolic | 73.00 [66.00, 79.00] | 73.00 [67.50, 78.00] |
| Heart rate (median, [IQR]) | 77.00 [68.00, 83.00] | 75.00 [66.50, 83.00] |
| Weight (median, [IQR]) | 64.40 [57.05, 74.15] | 63.60 [56.10, 71.50] |
| Height (median, [IQR]) | 1.65 [1.60, 1.70] | 1.64 [1.58, 1.70] |
| Comorbidities a n (%) | 64 (42.4) | 56 (34.4) |
| Risk factor for severe COVID-19 b | 24 (15.9) | 16 (9.8) |
| Hypertension c | 6 (4.0) | 4 (2.5) |
| Dyslipidemia c | 4 (2.6) | 3 (1.8) |
| Neoplasia c | 6 (4.0) | 2 (1.2) |
| Respiratory diseases c | 8 (5.3) | 7 (4.3) |
| Obesity c | 0 (0.0) | 1 (0.6) |
| Heart diseases c | 1 (0.6) | 0 (0.0) |
a Number of participants presenting at least one comorbidity. b Number of participants presenting at least one risk factor for severe COVID-19. c Number of participants presenting each of the risk factors for severe COVID-19.